Publications
43
Citations
618
Est. group size
—
Recurring co-author estimate
Active years
35
Publishing since 1992
Emily A. Smith's research focuses on discovering and chemically studying natural products—chemical compounds derived from marine organisms (sponges, corals), fungi, and other microbes—to find new inhibitors of enzymes involved in cancer-related cell signaling, such as protein kinases and ubiquitin ligases. This work combines natural product chemistry, organic synthesis, and biochemical/cell-based testing to evaluate how these compounds might affect cancer cell growth, including cholangiocarcinoma, Merkel cell carcinoma, and adrenocortical carcinoma. Students in this area would likely engage in isolating and characterizing new chemical compounds and testing their biological activity against disease-relevant protein targets.
Publication output has been fairly steady over the last decade, with year-to-year fluctuations but a consistent average of roughly 3 papers per year in the most recent five-year period.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Chemical Evolution of Aplithianine Class of Serine/Threonine Kinase Inhibitors
Journal of Medicinal Chemistry · 2025
- Abstract 6915: Cytoplasmic complex of SLK-XPO7: A targetable player in extrahepatic cholangiocarcinoma
Cancer Research · 2025
- Adrenocortical carcinoma metastasis organoids reveal heterogeneity & drug-insensitivity in the liver
HPB · 2025
- Formation of Trideuteromethylated Artifacts of Pyrrole-Containing Natural Products
Journal of Natural Products · 2024
- Acroamine A, a 2-Amino Adenine Alkaloid from the Marine Soft Coral <i>Acrozoanthus australiae</i> and Its Semisynthetic Derivatives That Inhibit cAMP-Dependent Protein Kinase A Catalytic Subunit Alpha
Journal of Natural Products · 2024
- Chemoreactive 2,5-Diketopiperazines from a <i>Penicillium</i> sp., Structure Revision of Reported Analogues and Proposed Facile Transformation Pathways
Journal of Natural Products · 2024
- Abstract LB172: A cytosolic complex between exportin-7(XPO7) and ste20-like kinase (SLK) regulates PI3K-AKT-mTOR signaling in cholangiocarcinoma
Cancer Research · 2024
- An Investigation of Structure–Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells
Marine Drugs · 2023
- Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases
Journal of Natural Products · 2023
- Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3′,5′-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors
ACS Pharmacology & Translational Science · 2023
- Natural Products as a Source of Chemical Diversity in cyclic-AMP dependent Protein Kinase A (PKA) Inhibitor Discovery
Journal of Pharmacology and Experimental Therapeutics · 2023
- Tolypocladamides A–G: Cytotoxic Peptaibols from <i>Tolypocladium inflatum</i>
Journal of Natural Products · 2022
- Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-B
Organic Letters · 2022
- Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction
Molecular Cancer Therapeutics · 2021
- Roseabol A, a New Peptaibol from the Fungus Clonostachys rosea
Molecules · 2021
- Journal of Natural Products×8
- Gynecologic Oncology×6
- Cancer Research×3
- Marine Drugs×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Qingfei Zheng
Medicine · The Ohio State University
- Liwen Zhang
Medicine · The Ohio State University
- César Aguilar
Medicine · Purdue University West Lafayette
- Jeremy R. Lohman
Medicine · Purdue University West Lafayette
- Jerry Cui
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile